Sakar Healthcare Reports Strong Q2 FY27 Results Driven by Oncology Expansion
Sakar Healthcare Ltd 路 Transcript 路 02 Nov 2026, 9:46 pm
Sakar Healthcare Reports Strong Q2 FY27 Results Driven by Oncology Expansion Sakar Healthcare reported robust Q2 FY27 performance, with operational revenue rising 52% YoY to INR 8,741.61 lakhs, EBITDA jumping 114% YoY to INR 2,434.53 lakhs (margin at 28% vs. 20%), and PAT surging 149% YoY to INR 1,130.69 lakhs. Management targets over 35% revenue growth and expects overall quarterly revenue to cross INR 100 crores from Q3. In oncology, API backward integration and upcoming global commercializations are projected to expand EBITDA margins toward 35% over the next two years.
Original exchange filing (PDF)
More announcements from Sakar Healthcare Ltd
- Sakar Healthcare Limited has informed the Exchange about Link of Recording 路 27 Oct 2026
- Sakar Healthcare Limited has informed the Exchange about Investor Presentation 路 26 Oct 2026
- Sakar Healthcare Limited has informed the Exchange regarding a press release dated October 26, 2026, titled "Press Release - Consolidated and Standalone Unaudited Financial Results for the quarter and half year ended September 30, 2026". 路 26 Oct 2026
- Sakar Healthcare Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026. 路 23 Oct 2026
- Sakar Healthcare Limited has informed the Exchange about Schedule of meet 路 27 Oct 2026
- SAKAR HEALTHCARE LIMITED has informed the Exchange about Board Meeting to be held on 23-Oct-2026 to consider and approve the Quarterly Unaudited Financial results of the Company for the period ended September 2026 and Other business. 路 23 Oct 2026
- To consider and approve the financial results for the period ended September 30, 2026 and other business matters 路 23 Oct 2026
- Sakar Healthcare Limited has informed the Exchange about Sakar s global export model expands with oncology products 路 14 Oct 2026
